Is entrectinib/Luoshengquan a targeted drug or a chemotherapy drug?

Entrectinib(Entrectinib) is a targeted therapy drug rather than a traditional chemotherapy drug. As a small molecule tyrosine kinase inhibitor, entrectinib prevents the growth and spread of cancer cells by selectively targeting the neurotrophic tyrosine receptor kinase (NTRK) fusion gene, ROS1 gene mutations and other related molecular pathways.

Unlike chemotherapy drugs, entrectinib's mechanism of action is more precise and specifically targets the molecular mechanisms associated with specific gene mutations or fusions. Chemotherapy drugs usually inhibit tumor growth by affecting the cell division process, but because they do not specifically act on cancer cells, chemotherapy drugs often affect normal cells in the body, causing a wide range of side effects. In contrast, targeted drugs like entrectinib reduce damage to normal cells by targeting molecular targets unique to cancer cells, and generally have fewer side effects.

Enrectinib is mainly used to treat NTRK fusion gene-positive solid tumors and ROS1-positive non-small cell lung cancer (NSCLC). These gene mutations and fusions are often drivers of cancer cell proliferation and metastasis, and entrectinib can treat cancer by inhibiting these gene pathways. Because entrectinib only acts on specific molecular targets, it has higher therapeutic specificity and better tolerability, and can significantly improve patients' quality of life.

In general, entrectinib, as a targeted drug, provides cancer patients with a more precise treatment. The use of entrectinib continues to expand. Compared with chemotherapy drugs, targeted drugs have fewer side effects and can better match a patient's genetic profile, thereby improving treatment effectiveness.

Reference materials:https://www.roche.com/products/rozlytrek